RICTOR

Overview

RICTOR is a core component of the mTORC2 complex. In the corpus it is highlighted as a subclonal resistance driver detectable by ctDNA in advanced NSCLC.

Alterations observed in the corpus

  • Enriched among ctDNA-only alterations (not detected by time-matched tissue sequencing) in the 1,127-patient prospective NSCLC ctDNA cohort; flagged as a subclonal driver of resistance associated with short survival PMID:36357680.
  • Recurrent copy number amplifications and mutations in RICTOR detected in melanoma WES cohort (147 tumors, Yale); identified as significantly mutated gene PMID:22842228
  • RICTOR high expression supported mTOR-inhibitor (everolimus) recommendations in neuroendocrine neoplasms PN4 and PN25 within a WGTA-guided precision oncology cohort PMID:24326773
  • RICTOR (MTORC2 component) part of PI3K/AKT/MTOR pathway alterations present in 84% of ULMS+STLMS C1 vs 44% of STLMS C2 sarcoma; nominates dual PI3K/MTOR or TORC1/TORC2 inhibitors as therapeutic strategy PMID:29100075

Cancer types (linked)

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • No direct therapeutic link reported; flagged as potentially relevant to resistance management PMID:36357680.

Open questions

  • Whether ctDNA-only RICTOR subclonal alterations should directly alter NSCLC treatment selection remains an open cross-paper question PMID:36357680.

Sources

This page was processed by crosslinker on 2026-05-09. - PMID:22842228

This page was processed by crosslinker on 2026-05-09. - PMID:24326773

This page was processed by crosslinker on 2026-05-09. - PMID:29100075

This page was processed by wiki-cli on 2026-05-15.